<DOC>
	<DOCNO>NCT00650104</DOCNO>
	<brief_summary>The purpose study obtain information long-term safety , tolerability , therapeutic benefit extend release ropinirole XL , provide mechanism patient participate either Study 167 Study 164 continue receive ropinirole XL chose .</brief_summary>
	<brief_title>Long-term Extension Study Evaluating Extended Release Ropinirole XL ( Formerly Referred Ropinirole CR ) Patients Who Already Completed Either Study 167 164</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Males nonpregnant/nonbreast feed female At least 30 year age Diagnosis idiopathic Parkinson '' disease ( Hoehn &amp; Yahr criterion ) Completed either Study 167 Study 164 Presence uncontrolled psychiatric , hematological , renal , hepatic , endocrinological , neurological , cardiovascular disease active malignancy Dizziness fainting due orthostatic hypotension stand Significant sleep disorder Drug abuse alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>ropinirole IR</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>open-label</keyword>
	<keyword>long term safety ; REQUIP</keyword>
	<keyword>ropinirole XL</keyword>
	<keyword>ropinirole CR</keyword>
	<keyword>Parkinson 's disease</keyword>
</DOC>